Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
PT-141 (bremelanotide) is a derivative of MT-II that was specifically modified to target MC4R for sexual dysfunction
HF is a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality affecting more than 60 million people worldwide (Groenewegen et al., 2020)
Specific research areas include: Regulation of nitric oxide and endothelial signaling pathways Actin dynamics and cell migration processes Extracellular matrix deposition and remodeling Oxidative stress mitigation and redox balance Modulation of gene expression related to repair and immune signaling The combined formulation allows for the evaluation of overlapping and divergent signaling effects without the need for parallel administration protocols
.png)
Lorena Crosa es licenciada en Qumica y Farmacia en la Universidad de la Repblica (2000 2004)
US$ 27.03
US$ 24.05
US$ 28.69
